Fedratinib Hydrochloride and Lo/Ovral-28
Determining the interaction of Fedratinib Hydrochloride and Lo/Ovral-28 and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes. Coadministration of fedratinib with a single dose each of the CYP450 3A4 substrate midazolam (2 mg), CYP450 2C19 substrate omeprazole (20 mg), and CYP450 2D6 substrate metoprolol (100 mg) increased the systemic exposure (AUC) of the substrates by 4-, 3-, and 2-fold, respectively. MANAGEMENT: Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index. References "Product Information. Inrebic (fedratinib)." Celgene Corporation, Summit, NJ.
Professional:MONITOR: Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes. Coadministration of fedratinib with a single dose each of the CYP450 3A4 substrate midazolam (2 mg), CYP450 2C19 substrate omeprazole (20 mg), and CYP450 2D6 substrate metoprolol (100 mg) increased the systemic exposure (AUC) of the substrates by 4-, 3-, and 2-fold, respectively.
MANAGEMENT: Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.
- "Product Information. Inrebic (fedratinib)." Celgene Corporation, Summit, NJ.
Generic Name: fedratinib
Brand name: Inrebic
Synonyms: Fedratinib
Generic Name: ethinyl estradiol / norgestrel
Brand name: Cryselle 28, Low-Ogestrel, Ogestrel-28, Cryselle-28, Elinest, Ogestrel, Lo/Ovral-21, Lo/Ovral-28, Ovral, Ovral-28, Low-Ogestrel-21, Ovral-21
Synonyms: Lo/Ovral-28 (Oral), Lo Ovral 28
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fedratinib Hydrochloride-Locoid
- Fedratinib Hydrochloride-Locoid Cream
- Fedratinib Hydrochloride-Locoid Lipocream
- Fedratinib Hydrochloride-Locoid Lipocream Topical application
- Fedratinib Hydrochloride-Locoid Lotion
- Fedratinib Hydrochloride-Locoid Ointment
- Lo/Ovral-28-Feiba
- Lo/Ovral-28-Feiba NF
- Lo/Ovral-28-Feiba VH Immuno
- Lo/Ovral-28-Feiba-VH
- Lo/Ovral-28-Felbamate
- Lo/Ovral-28-Felbamate Oral Suspension